Novici Biotech is a privately owned company that provides DNA error correction technology for the synthetic biology industry and develops recombinant antibodies, enzymes, and other proteins in plants.
Novici provides two DNA correction technologies, ErrASE and DirectASE, and has a third product in development. ErrASE, available since 2009, is an enzymatic error correction technology for gene synthesis. The DirectASE technology requires less time to amend errors in synthetic gene fragments.
The company specializes in enhancing recombinant protein targets in the benth plant or “Nicotiana benthamiana” through the use of synthetic biology techniques. The process optimizes target protein yield, stability, and post-translational modification with the company’s engineering strategies. The features of recombinant protein expression in plants include reduced development time, affordability, scalability, reduced contamination (as it is animal-free), and a higher eukaryote host with active proteins.
For its DNA libraries, Novici has its Genetic ReAssortment by MisMatch Resolution (GRAMMR) technology that develops crop trait evolution for optimal performance and gene expression. GRAMMR can transform enzymes into desired traits and assess possibilities of codon usage through directed evolution.
Key customers and partnerships
Novici Biotech licensed its ErrASE DNA correction technology to Life Technologies Corporation in October 2010 and its GRAMMR genetic reassortment technology to Intrexon Corporation in May 2011.
In October 2014, Novici expanded its partnership with iBio, Inc. to combine its GRAMMR technology to increase the expression yield of target proteins as part of the objective of extending the focus of antibodies and vaccine products to include iBio's IBIO-CFB03 product.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.